Determine the effect of treatment with INCB013739 administered as an 'add-on' to metformin therapy in type 2 diabetic subjects on safety and tolerability and glycemic control.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
302
INCB013739 5 mg QD tablet
INCB013739 15 mg QD tablet
INCB013739 50 mg QD tablet
Change from Baseline to Week 12 in hemoglobin A1c (HbA1c)
Time frame: Baseline and Week 12 (or early termination study visit)
Change from Baseline to Week 12 in fasting plasma glucose (FPG).
Time frame: Baseline and Week 12 (or early termination study visit)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
INCB013739 100 mg QD tablet
INCB013739 200 mg QD
Orally once daily tablet
Unnamed facility
Birmingham, Alabama, United States
Unnamed facility
Artesia, California, United States
Unnamed facility
Calabasas, California, United States
Unnamed facility
Fresno, California, United States
Unnamed facility
Los Angeles, California, United States
Unnamed facility
Los Gatos, California, United States
Unnamed facility
Santa Ana, California, United States
Unnamed facility
Colorado Springs, Colorado, United States
Unnamed facility
Chiefland, Florida, United States
Unnamed facility
Hollywood, Florida, United States
...and 58 more locations